KRAS Mutations – Non-Small Cell Lung Cancer

Dr. Chadi Nabhan, Chairman of Precision Oncology Alliance™ at Caris Life Sciences® and Dr. Stephen Liu, an oncologist with Medstar Health and an investigator on this study discuss the data presentation from the American Society of Clinical Oncology, (ASCO20) Virtual Scientific Program, Abstract 9544/Poster 310: Characterization of KRAS mutations in non-small cell lung cancer (NSCLC).

Dr. Chadi Nabhan joined Caris Life Sciences® in April of 2020 as Chairman of Precision Oncology Alliance™. As chairman, Dr. Nabhan leads a collaborative network of leading cancer centers that demonstrates a commitment to precision medicine. Prior to joining Caris  Dr. Nabhan was Chief Medical Officer of Aptitude Health, a global provider of oncology insights. He was also Chief Medical Officer at Cardinal Health Specialty Solutions where he led clinical programs, real-world evidence, HEOR, regulatory, publications and strategic initiatives for key stakeholders. Previously, Dr. Nabhan was an Associate Professor of Medicine, and Medical Director of the Clinical Cancer Center at the University of Chicago where he oversaw the clinical operations of cancer clinics and supervised all aspects of cancer care delivery. He is currently an Adjunct Professor in the Department of Clinical Pharmacy at the University of South Carolina.Dr. Nabhan maintains active medical licenses in five states, has over 300 peer-reviewed articles and abstracts, and has hosted his own award-winning healthcare podcast named “Outspoken Oncology” since February 2019.

Liked it? Take a second to support healthprofessionalradio on Patreon!
Become a patron at Patreon!


Leave a Reply

You must be logged in to post a comment.